Avalon GloboCare Corp. (NASDAQ:ALBT) Sees Large Decrease in Short Interest

Avalon GloboCare Corp. (NASDAQ:ALBT) was the target of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 7,200 shares, a decline of 63.6% from the January 15th total of 19,800 shares. Based on an average daily trading volume, of 841,400 shares, the short-interest ratio is presently 0.0 days. Currently, 1.7% of the shares of the stock are short sold.

Avalon GloboCare Price Performance

Avalon GloboCare stock opened at $3.69 on Friday. The firm has a market cap of $4.02 million, a PE ratio of -0.18 and a beta of 0.19. The stock’s fifty day moving average price is $3.61 and its two-hundred day moving average price is $3.60. Avalon GloboCare has a one year low of $2.11 and a one year high of $21.60.

Avalon GloboCare (NASDAQ:ALBT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.82) EPS for the quarter. The company had revenue of $0.35 million during the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.